Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. - Wikidata - wikimedia - TriplyDB

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

http://www.wikidata.org/entity/Q38922304

about

Persistent androgen receptor addiction in castration-resistant prostate cancer Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model Environmental endocrine disruptors: Effects on the human male reproductive system A Urologist's Personal View of Prostate Cancer Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy Androgen receptor splice variants and prostate cancer: From bench to bedside.Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Androgen pathway resistance in prostate cancer and therapeutic implications Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.Testosterone therapy and prostate cancer.'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.Low Testosterone Alters the Activity of Mouse Prostate Stem Cells.Application of Evolutionary Principles to Cancer Therapy Testosterone Therapy in Men With Prostate Cancer.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.Transient exposure to androgens induces a remarkable self-sustained quiescent state in dispersed prostate cancer cells.Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Phosphorylation-induced conformational dynamics in an intrinsically disordered protein and potential role in phenotypic heterogeneity.Testosterone Therapy Among Prostate Cancer Survivors.Harnessing Solute Carrier Transporters for Precision Oncology.Treatment strategies for DNA repair-deficient prostate cancer.From bench to bedside: bipolar androgen therapy in a pilot clinical study.Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.TGF-β Conveys Undesirable Side Effects of Androgen Depletion.Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer.Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction.Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.Effects of Testosterone on Benign and Malignant Conditions of the Prostate.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways.

P2860

Q26777163-07147588-2C3D-4AC7-93B7-77144B84B2F2 Q26778886-C8F4FFAD-E1FC-4EB4-AB37-9BF194FBDE7C Q28070418-2D49825A-9ADD-4231-8AA0-0A6C442A8DD1 Q28072919-B9958B45-49E1-4056-AFCF-ED29E5A6A8BD Q28829239-910F85BE-7BD1-4813-BFC4-5AE193334506 Q33567024-F0CE8B74-6EAE-4081-8BBB-D565E843D2B0 Q33624448-06A427DF-CC36-48A9-9A68-77CDF149F282 Q36416370-664D5211-AB96-4A9A-AB38-ACE2407F2567 Q36586089-B584D173-CF7E-4B01-AAEC-B0EFED0376AA Q37059814-5141A49B-9448-4C9C-930D-E6B69FA618D8 Q37302524-A9C3E081-BD11-482A-9B2C-03C80234AFAF Q37531045-25A15087-CE15-42F0-85EC-45DA167E74B6 Q38366829-E7F4E691-2F49-40F8-A0F9-932AB4476CB8 Q38439120-145B67B0-8245-40CC-80C5-F0C2DE4E0737 Q38623060-80F7874A-CA5D-4E90-8B28-C6BF0833A3CF Q38683604-724B3B88-9B66-440F-B5EF-334DE3A508AD Q38765489-3964EB7D-E93F-492A-9D94-50AA2B5FA4FD Q38766081-35277AFF-E921-4A18-BD8B-29D043BC4754 Q38775459-5D75723A-54F4-40DF-AE8D-8DABDBB627FD Q38810776-CD78ECEA-1168-457D-B1D8-0A58CD75221A Q38828800-75E49D82-B9A2-4A89-AE39-827D4585C1B9 Q38835693-D11F357E-C63A-4A59-B53B-1B529B906815 Q38910392-26E09848-B597-45A7-93D9-7CA208BA14E2 Q38913362-D02CAD82-982F-49B5-AE68-F56A88149E6D Q39204754-803DD090-599D-4AB6-9D1D-DC06F9077467 Q39345771-D4C5F497-AD91-4020-A951-9800B8F97EF0 Q42120157-AF056A0A-9820-440E-B99D-9FF2D5F03B8A Q42363301-DDCE15FB-EB1D-4FB6-92AE-739688F77AD8 Q42724556-AC309D24-A307-4B5F-AD40-43E7E15D87B1 Q42908815-3039ED20-EC24-4B21-A364-1F7B74EB002D Q43969195-D5BBF420-9A0F-428F-825F-A479C380EBC7 Q45058251-1F0E4836-D7DF-4535-AC3F-09BB88F19D1D Q47094315-5EDB2824-E15A-4FDE-AB29-83D947B5D82A Q47097550-1ABAE9F7-4A9F-4420-B20B-9ED616012D35 Q47191382-0AB7F404-F612-4439-A2AC-D80F67938941 Q47359141-CC9352BF-F680-42DD-BDC7-DFB5FA0F850D Q47716531-3A54831C-88A4-43E6-A7A6-CFF8D4D443C5 Q47746789-DF9355A4-1715-4124-A873-B98C1E3BC454 Q47825566-902BA27E-A852-4466-AC28-1F3850286193 Q49959247-6414F656-4F51-485B-AB07-25FB43781B18

P2860

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

http://www.wikidata.org/entity/Q38922304

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Effect of bipolar androgen the ...... s from a pilot clinical study.

@en

type

label

Effect of bipolar androgen the ...... s from a pilot clinical study.

@en

prefLabel

Effect of bipolar androgen the ...... s from a pilot clinical study.

@en

P1433

Q38922304-2E1EF8A2-8276-417A-896A-2D040029F1ED

P1476

Q38922304-5438FACE-DA0B-458F-A482-5DCC7E476DEA

P2093

Q38922304-047ACBAB-5084-4F95-8462-D3664D7CC145

Q38922304-09C33388-97C5-4FDE-B402-D5027AA9F147

Q38922304-0B4BCC92-3149-4D22-A405-74839146CCF9

Q38922304-2E732996-D348-435D-A7F2-CE8F1370F04E

Q38922304-564C0BB0-96D8-445C-999B-5F79A575AB27

Q38922304-63C28E4D-0D5E-4473-A080-BE79104B8089

Q38922304-85B9A605-9914-46A8-AC37-92F8B8F5399F

Q38922304-902FA520-C1D6-4D00-BAD4-55E127DB2672

Q38922304-92C67069-B140-4207-BFD6-08FB07D4A959

Q38922304-93647F94-8FA3-46A1-A3BE-CF446D6EA273

P2860

Q38922304-0301AD3C-55CC-43ED-A9D3-ABFC608E2AE9

Q38922304-03B48149-1B79-47FC-99C1-4DD3D833D1C7

Q38922304-0A6CD171-860B-4698-89BC-C3E088DAAF32

Q38922304-161F9782-724D-4D39-87D4-E84A14C1B301

Q38922304-1767B469-353C-445E-A21B-FC27A9A2A447

Q38922304-1A096099-37F1-4B43-8ED0-591F431E7FFC

Q38922304-1A1AE898-7CF1-4459-A531-59A78763BA0D

Q38922304-27B32D88-2393-4FF6-9B91-5455510D2FCF

Q38922304-28185C8C-CFCA-403A-812F-AD211E91ACEE

Q38922304-303F45E7-7D0C-42E9-B814-534A5794502E

P304

Q38922304-8282ABDD-A9A8-4622-83FB-308E29FE6BEE

P31

Q38922304-3E8572AC-87AF-4FC1-A59A-3822F73F24BC

P356

Q38922304-DF2D634B-5765-4BEA-8734-AED099009774

P407

Q38922304-F12DC360-1D79-44CF-86BF-808A7BE31F1C

P433

Q38922304-E992BFFA-7E28-43AD-A5DE-0B90FBCDC72C

P478

Q38922304-2E52ADB7-EDE1-4C8A-AA31-B878439DFB7A

P577

Q38922304-9E0642B4-2AB7-4DCB-A072-F5AB42120BEA

P698

Q38922304-656ABBAC-B503-4E37-9DA7-16F64ACA5728

P932

Q38922304-1136D9E0-718F-4CE8-B9DF-7E94C42D8BF5

P356

SCITRANSLMED.3010563

P1433

Science Translational Medicine

P1476

Effect of bipolar androgen the ...... s from a pilot clinical study.

@en

P2093

A Seun Ajiboye

http://www.w3.org/2001/XMLSchema#string

Avery Spitz

http://www.w3.org/2001/XMLSchema#string

Emmanuel S Antonarakis

http://www.w3.org/2001/XMLSchema#string

Haiyi Cao

http://www.w3.org/2001/XMLSchema#string

Hao Wang

http://www.w3.org/2001/XMLSchema#string

John T Isaacs

http://www.w3.org/2001/XMLSchema#string

Jun Luo

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Michael C Haffner

http://www.w3.org/2001/XMLSchema#string

P2860

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

Abiraterone in metastatic prostate cancer without previous chemotherapy

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Molecular determinants of resistance to antiandrogen therapy

The mutational landscape of lethal castration-resistant prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Ras signaling in prostate cancer progression.

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

P304

269ra2

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3010563

http://www.w3.org/2001/XMLSchema#string

P407

P433

269

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25568070

http://www.w3.org/2001/XMLSchema#string

P932

4507510

http://www.w3.org/2001/XMLSchema#string